Google
×
Our proprietary thermally stable oral vaccine platform technology, OraPro, enables the provision of vaccines in a tablet, capsule or nasal spray. This ground- ...
Stabilitech · enables oral administration of non-replicating vector · enables repeat administration with the same vector carrying the same or new payload ...
Sep 30, 2020 · PRESS RELEASE Stabilitech Biopharma announces name change to iosBio Burgess Hill, UK, 30 September 2020, STABILITECH BIOPHARMA (the ...
The Auckland-based company has 30 years' experience in manufacturing viral vaccines, with its recent acquisition of Living Cell Technology's GMP compliant cell ...
May 1, 2020 · Stabilitech, a UK biotechnology company which develops next-generation vaccines and biopharmaceuticals, is seeking an investment of £6 million ...
Nov 10, 2021 · Here, a biopolymer particle (BP) vaccine technology that can be quickly adapted to new and emerging variants of SARS-CoV-2 is used. Coronavirus ...
Stabilitech Ltd. develops technologies for the stabilization of biological molecules such as vaccines and bio-pharmeceuticals.
Mar 26, 2020 · Stabilitech's OraPro-COVID-19 vaccine development aims to deliver in 3 months an oral vaccine with two unique properties, capsule administration ...
Jul 3, 2020 · This thermally stable vaccine has many advantages: it provides both systemic and mucosal immunity, the time to immunity is only 2-3 weeks, ...
Stabilitech is a privately held company focused on stabilisation of sensitive biological molecules, such as vaccines and biopharmaceuticals.